Telmisartan and Hydrochlorothiazide Antihypertensive Treatment Study in High Sodium Intake Population

NACompletedINTERVENTIONAL
Enrollment

1,410

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

March 31, 2015

Conditions
Hypertension
Interventions
DRUG

Telmisartan

capsule,40mg per day,2 months

DRUG

Hydrochlorothiazide

tablet, 25mg per day, 2 months

Trial Locations (14)

071200

Chinese Traditional Medicine Hospital of Anguo, Baoding

071300

Boye hospital, Baoding

071400

Lixian chinese traditional medicine hospital, Baoding

071500

Gaoyang hospital, Baoding

071700

People's hospital in Rongcheng, Baoding

072150

Mancheng Hospital, Baoding

072250

Shunping Hospital, Baoding

072350

People's hospital of Tangxian, Baoding

072450

Wangdu hospital, Baoding

074000

Gaobeidian hospital, Baoding

074004

Central hospital in Baigou, Baoding

074100

The second hospital of Lai Shui, Baoding

065800

Wenan Hospital, Lanfang

065900

Dacheng chinese traditional medicine hospital, Langfang

All Listed Sponsors
collaborator

Peking University People's Hospital

OTHER

lead

The George Institute for Global Health, China

OTHER

NCT02255253 - Telmisartan and Hydrochlorothiazide Antihypertensive Treatment Study in High Sodium Intake Population | Biotech Hunter | Biotech Hunter